LAVA Therapeutics reveals a partnership with Merck & Co., US, to assess the potential of combining LAVA-1207 with the treatment, KEYTRUDA®.

Ibuprofen, a COX-inhibiting drug approved by Johnson & Johnson in 1978, is primarily used to manage rheumatoid arthritis, arthritis, fever, and pain.

Metoprolol Tartrate is a medication that blocks β-adrenoceptors, and it was approved in 1978 by AstraZeneca PLC.

Sionna Therapeutics has revealed the administration of the initial dose to a healthy participant in the Stage 1 clinical study for SION-109.

Atorvastatin is a medication that inhibits the HMG-CoA reductase enzyme. Hanmi Pharmaceutical Co., Ltd approved it in January 2008.

Sciwind Biosciences Reports Encouraging Outcomes from Initial Clinical Study of XW004, Its Oral Version of Sustained-Release GLP-1 Mimetic Ecnoglutide.

Trazodone, a selective inhibitor of serotonin reuptake transporter 5, has been a key treatment for depression since its approval in Dec 1981 by Angelini Pharma.

Acetaminophen, a small molecule COX enzyme inhibitor drug approved in January 1966, is widely used for pain relief and fever reduction.

Locus Biosciences has disclosed receiving a $23.9 million investment from BARDA, intended to back the inaugural Phase 2 study of its groundbreaking CRISPR-crafted phage treatment.

Metronidazole, a small molecule drug approved in 1960 by Pfizer Inc., inhibits DNA synthesis and is highly effective against anaerobic bacteria and protozoa.

Onward Therapeutics has begun recruiting for an initial phase clinical study of their innovative dual-targeted antibody, OT-A201, which engages with two distinct immune control points.

Pantoprazole is a small molecule medicine classed as a proton pump inhibitor, which means it reduces the amount of acid generated in the stomach.